Insmed's Brensocatib Fails Phase 2b HS Study; Program Discontinued

summarizeSummary

Insmed announced that its Phase 2b CEDAR study for brensocatib in hidradenitis suppurativa (HS) failed to meet its primary and secondary efficacy endpoints, leading to the discontinuation of the development program for this indication.

check_boxKey Events

• Phase 2b Study Failure

  The Phase 2b CEDAR study of brensocatib in patients with hidradenitis suppurativa (HS) did not meet its primary or secondary efficacy endpoints.

• Program Discontinuation

  Insmed will discontinue its development program of brensocatib in hidradenitis suppurativa due to the study results.

• Efficacy Outperformed by Placebo

  At Week 16, the placebo arm showed a 57.1% reduction in total abscess and inflammatory nodule (AN) count, which was superior to brensocatib's 45.5% (10 mg) and 40.3% (40 mg) reductions.

• Safety Profile Consistent

  Brensocatib was well tolerated, with no new safety signals identified in the study.

auto_awesomeAnalysis

Insmed announced the failure of its Phase 2b CEDAR study for brensocatib in hidradenitis suppurativa (HS), with the drug failing to meet its primary and secondary efficacy endpoints. Notably, the placebo arm demonstrated a superior reduction in inflammatory lesions compared to both brensocatib treatment arms. This outcome has led to the immediate discontinuation of the brensocatib development program for HS, representing a significant setback for the company's pipeline and future revenue potential in this indication. While the company has other approved therapies and a diverse pipeline, the termination of a mid-stage program is a material negative event that will likely impact investor sentiment and the stock price.